{"id":970082,"date":"2026-06-03T08:39:16","date_gmt":"2026-06-03T12:39:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/"},"modified":"2026-06-03T08:39:16","modified_gmt":"2026-06-03T12:39:16","slug":"neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/","title":{"rendered":"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuum<\/li>\n<li>New data demonstrate the effect of CRENESSITY on long-term androgen control and glucocorticoid dose reduction and associated clinical outcomes<\/li>\n<li>Data from cross-sectional surveys highlight patient- and caregiver-reported quality of life improvements<\/li>\n<li>Case series highlights use of CRENESSITY in patients with classic CAH due to 11\u03b2\u2011hydroxylase deficiency<\/li>\n<li>Additional ENDO 2026 presentations include VYKAT\u2122 XR (diazoxide choline) extended-release tablets data in hyperphagia associated with Prader-Willi syndrome (PWS), including late-breaking long-term extension findings following randomized withdrawal, and data evaluating sustained improvements in hyperphagia and behavioral symptoms through three years<\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\">SAN DIEGO<\/span>, <span class=\"legendSpanClass\">June 3, 2026<\/span> \/PRNewswire\/ &#8212; <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=2979741158&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.\" target=\"_blank\" rel=\"nofollow\">Neurocrine Biosciences, Inc.<\/a> (Nasdaq: NBIX) today announced it will present multiple new analyses of key clinical and patient-reported outcomes up to two years of treatment with <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=1898909079&amp;u=https%3A%2F%2Fwww.crenessity.com%2F&amp;a=CRENESSITY%C2%AE+(crinecerfont)\" target=\"_blank\" rel=\"nofollow\">CRENESSITY<sup>\u00ae<\/sup> (crinecerfont)<\/a> in adult and pediatric populations with classic congenital adrenal hyperplasia. These data will be presented at the Endocrine Society&#8217;s annual meeting, ENDO 2026, taking place from June 13-16, in Chicago.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg\" title=\"(PRNewsfoto\/Neurocrine Biosciences, Inc.)\" alt=\"(PRNewsfoto\/Neurocrine Biosciences, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The presentations will highlight the breadth of data generated from the CAHtalyst<sup>\u00ae<\/sup> clinical program&#8217;s long\u2011term extension studies, reflecting Neurocrine&#8217;s continued focus on advancing ongoing disease management in classic congenital adrenal hyperplasia (CAH). The data build on prior scientific presentations at recent medical meetings, including the <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=523171261&amp;u=https%3A%2F%2Fneurocrine.gcs-web.com%2Fnews-releases%2Fnews-release-details%2Fneurocrine-biosciences-presents-new-two-year-crenessityr&amp;a=American+Association+of+Clinical+Endocrinology+2026+Annual+Meeting\" target=\"_blank\" rel=\"nofollow\">American Association of Clinical Endocrinology 2026 Annual Meeting<\/a> and the <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=4258762901&amp;u=https%3A%2F%2Fneurocrine.gcs-web.com%2Fnews-releases%2Fnews-release-details%2Fneurocrine-biosciences-presents-new-two-year-crenessityr-0&amp;a=Pediatric+Endocrine+Society+2026+Annual+Meeting\" target=\"_blank\" rel=\"nofollow\">Pediatric Endocrine Society 2026 Annual Meeting<\/a>. Together, these analyses extend the evaluation of longer\u2011term clinical and patient\u2011relevant outcomes associated with sustained androgen control and reduced glucocorticoid (GC) exposure.<\/p>\n<p>&#8220;At ENDO 2026, we look forward to presenting compelling two-year treatment outcomes in patients with classic CAH treated with CRENESSITY,&#8221; said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. &#8220;These data support the growing body of evidence around the meaningful long-term benefits of improved androgen\u00a0control\u00a0together with reduced exposure to high-dose glucocorticoids. This is the promise of treatment with CRENESSITY, which, together with lower-dose glucocorticoids, is rapidly becoming the new standard of care in classic CAH.&#8221;\u00a0<\/p>\n<p>Across multiple adult and pediatric analyses presented at ENDO 2026, Neurocrine will share a range of endpoints intended to further characterize longer\u2011term outcomes relevant to patients and clinicians, including measures related to metabolic health, bone health, growth and development and patient\u2011reported quality of life.<\/p>\n<p>In addition, Neurocrine will present a case series on the use of CRENESSITY in patients with classic CAH due to 11\u03b2\u2011hydroxylase deficiency, the second most common type of classic CAH after 21-hydroxylase deficiency, representing approximately 5% of all cases.<\/p>\n<p>Neurocrine will share the following poster and oral presentations at ENDO 2026. All times are Central Time:<\/p>\n<p>\n        <u>CAHtalyst Adult Study Two-Year Results<\/u>\n      <\/p>\n<p>\n        <b>Title:<\/b> Weight-Related Outcomes and Insulin Resistance in Adults with Classic Congenital Adrenal Hyperplasia: 2-Year Results from the CAHtalyst Adult Study <b>(Oral Presentation #ORF32-07)<br \/><\/b><b>Authors:\u00a0<\/b>Oksana Hamidi, D.O., et al<br \/><b>Date\/Time:<\/b> June 14 from 2:55-3:10 PM<\/p>\n<p>\n        <b>Title:<\/b> Adults with Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the CAHtalyst Adult Study <b>(Poster Presentation #SUN-458)<br \/><\/b><b>Authors:\u00a0<\/b>Irina Bancos, M.D., et al<br \/><b>Date\/Time: <\/b>June 14 from 12:00-1:30 PM<\/p>\n<p>\n        <b>Title:<\/b> A Cross-sectional Survey on Quality of Life of Adults with Classic Congenital Adrenal Hyperplasia\u00a0in the United States Participating in\u00a0CAHtalyst Adult Open-Label Extension\u00a0Study <b>(Poster Presentation #SUN-467)<br \/><\/b><b>Authors:\u00a0<\/b>Sonal Vaid, M.D., et al<br \/><b>Date\/Time: <\/b>June\u00a014\u00a0from\u00a012:00-1:30\u00a0PM<\/p>\n<p>\n        <b>Title:<\/b> Bone Outcomes in Adults with Classic Congenital Adrenal Hyperplasia Treated with Crinecerfont for Up to 2 Years in CAHtalyst Adult Study <b>(Poster Presentation #SUN-468)<br \/><\/b><b>Authors:\u00a0<\/b><span>Maria <\/span>Vogiatzi<span>, M.D., <\/span>et<span> al<br \/><\/span><b>Date\/Time: <\/b>June 14 from 12:00-1:30 PM<\/p>\n<p>\n        <u>CAHtalyst Pediatric Study Two-Year Results<\/u>\n      <\/p>\n<p>\n        <b>Title:<\/b> Characterization of Children and Adolescents with Classic Congenital Adrenal Hyperplasia\u00a0Who Had Slowed Bone Age Progression and Improved Height Prediction with Crinecerfont <b>(Oral Presentation #ORF32-05)<br \/><\/b><b>Authors:\u00a0<\/b><span>Maria <\/span>Vogiatzi<span>, M.D., <\/span>et<span> al<br \/><\/span><b>Date\/Time: <\/b>June 14 from 2:25-2:40 PM<\/p>\n<p>\n        <b>Title:<\/b> Long-term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone \u2014 Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric <b>(Poster Presentation #SAT-465)<br \/><\/b><b>Authors:\u00a0<\/b>Natalie Nokoff, M.D., et al<br \/><b>Date\/Time: <\/b>June 13 from 12:15-1:45 PM<\/p>\n<p>\n        <b>Title:<\/b> Long-term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses \u2014 Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric <b>(Poster Presentation #SUN-465)<br \/><\/b><b>Authors:\u00a0<\/b>Kyriakie Sarafoglou, M.D., et al<br \/><b>Date\/Time: <\/b>June 14 from 12:00-1:30 PM<\/p>\n<p>\n        <u>Additional Presentations<\/u>\n      <\/p>\n<p>\n        <i>Classic CAH:<\/i>\n      <\/p>\n<p>\n        <b>Title:<\/b> Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry<b> (&#8220;New Therapies and Perspectives for Congenital Adrenal Hyperplasia and Adrenal Insufficiency&#8221; Rapid Fire Presentation #ORF32-02 and Poster Presentation #MON-495)<br \/><\/b><b>Authors:\u00a0<\/b>Oksana Lekarev, D.O., et al<br \/><b>Date\/Time: <\/b>June 14 from 1:50-1:55 PM (Rapid Fire) and June 15 from 9:00-2:00 PM (Poster)<\/p>\n<p>\n        <b>Title:<\/b> Crinecerfont Treatment of Classic Congenital Adrenal Hyperplasia Due to 11\u03b2-Hydroxylase Deficiency: A Case Series<b> (Poster Presentation #SAT-466)<br \/><\/b><b>Authors:\u00a0<\/b>Kyriakie<span><\/span>Sarafoglou<span>, M.D., <\/span>et<span> al<br \/><\/span><b>Date\/Time: <\/b>June 13 from 12:15-1:45 PM<\/p>\n<p>\n        <b>Title:<\/b> A Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic Congenital Adrenal Hyperplasia\u00a0<b>(Poster Presentation #SAT-459)<br \/><\/b><b>Authors:\u00a0<\/b>Ahmed<span><\/span>Khattab<span>, M.D., <\/span>et<span> al<br \/><\/span><b>Date\/Time: <\/b>June 13 from 12:15-1:45 PM<\/p>\n<p>\n        <i>PWS:<\/i>\n      <\/p>\n<p>\n        <b>Title: <\/b><br \/>\n        <i>(Late-breaker) <\/i>Efficacy and Safety of Resuming Diazoxide Choline Extended-Release after 16-Week Randomized Withdrawal in Prader-Willi Syndrome (Study C614) <b>(Poster Presentation #SUN-689)<br \/><\/b><b>Authors:\u00a0<\/b>Jennifer L. Miller, M.D., et al<br \/><b>Date\/Time: <\/b>June 14 from 12:00-1:30 PM<\/p>\n<p>\n        <b>Title: <\/b>Long-Term Reductions of Hyperphagia with Diazoxide Choline Extended-Release in Participants with\u00a0Prader-Willi Syndrome\u00a0<b>(Poster Presentation #SUN-688)<br \/><\/b><b>Authors:\u00a0<\/b>Evelien F. Gevers, M.D., Ph.D., et al<br \/><b>Date\/Time: <\/b>June 14 from 12:00-1:30 PM<\/p>\n<p>\n        <b>Title: <\/b>Impact of Long-Term Diazoxide Choline Extended-Release\u00a0Treatment and the Prader-Willi Syndrome Profile Questionnaire\u00a0<b>(&#8220;Hypothalamic and Genetic Disorders of Energy Balance&#8221; Rapid Fire Presentation #ORF44-02 and Poster Presentation #MON-690)<br \/><\/b><b>Authors:\u00a0<\/b>Evelien F. Gevers, M.D., Ph.D., et al<br \/><b>Date\/Time: <\/b>June 15 from 9:35-9:40 AM (Rapid Fire) and June 15 from 9:00-2:00 PM (Poster)<\/p>\n<p>\n        <b>Title: <\/b>Mortality Among Patients with Prader-Willi Syndrome (MAP-PWS): An Analysis of Healthcare Utilization in the Year Prior to Death Within a Single U.S. Payer<b> (Poster Presentation #MON-863)<br \/><\/b><b>Authors:\u00a0<\/b>Isabella Niu, M.D., et al<br \/><b>Date\/Time: <\/b>June 15 from 12:00-1:30 PM<\/p>\n<p>\n        <b>About Congenital Adrenal Hyperplasia<\/b>\u00a0<br \/>Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens. Severe enzyme deficiency leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are typically still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in adrenal crisis and even death.\u00a0<\/p>\n<p>Exogenous glucocorticoids (GCs) are necessary to correct the endogenous cortisol deficiency, but historically, doses higher than those needed for cortisol replacement (supraphysiologic) have been used to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens.\u00a0However, GC treatment at\u00a0supraphysiologic\u00a0doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular\u00a0disease\u00a0and osteoporosis. Additionally, long-term treatment with\u00a0supraphysiologic\u00a0GCs may have psychological and cognitive impacts, such as changes in mood and memory.\u00a0Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to\u00a0cardiometabolic and\u00a0fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs).\u00a0<\/p>\n<p>\n        <b>About CRENESSITY<\/b><br \/>\n        <b><br \/>\n          <sup>\u00ae<\/sup><br \/>\n        <\/b>\u00a0<b>(crinecerfont)<\/b><br \/>CRENESSITY is a potent and selective oral\u00a0corticotropin-releasing\u00a0factor type 1 receptor (CRF<sub>1<\/sub>)\u00a0antagonist\u00a0that reduces and controls excess\u00a0adrenocorticotropic\u00a0hormone (ACTH) and adrenal androgens through a\u00a0non-glucocorticoid\u00a0(GC) mechanism for the treatment of classic congenital adrenal\u00a0hyperplasia\u00a0(CAH). Antagonism of CRF<sub>1<\/sub>\u00a0receptors in the pituitary has been shown to decrease\u00a0ACTH\u00a0levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with\u00a0CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of\u00a0GCs\u00a0to replace missing\u00a0cortisol.\u00a0<\/p>\n<p>CRENESSITY comes in capsules and an oral solution. For adults 18 years\u202fof age\u202fand older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121\u202flbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121\u202flbs), the recommended dosage is\u202f100 mg\u202ftwice daily taken orally with a meal. Healthcare providers can work with patients to\u202fdetermine\u202fthe\u202fappropriate formulation\u202ffor use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement.\u202f\u00a0<\/p>\n<p>\n        <b>About the\u202fCAHtalyst<\/b><br \/>\n        <b><br \/>\n          <sup>\u00ae<\/sup><br \/>\n        <\/b><br \/>\n        <b> Studies<\/b><br \/>\n        <br \/>The Phase 3\u202fCAHtalyst\u202fglobal registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY<sup>\u00ae <\/sup>(crinecerfont)\u202fin children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The\u202fCAHtalyst\u202fstudies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients.\u202f\u202f\u00a0<\/p>\n<p>The\u202f<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=2252915667&amp;u=https%3A%2F%2Fwww.nejm.org%2Fdoi%2F10.1056%2FNEJMoa2404655&amp;a=CAHtalyst%E2%80%AFPediatric+study\" target=\"_blank\" rel=\"nofollow\">CAHtalyst\u202fPediatric study<\/a>\u00a0included 103 pediatric\u202fpatients\u202ffour to 17 years\u202fof age. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional\u202f24 weeks\u202fof CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were\u202fmaintained\u202for improved.\u202f\u202f<\/p>\n<p>The\u202f<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=237103861&amp;u=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2404656&amp;a=CAHtalyst%E2%80%AFAdult%E2%80%AFstudy\" target=\"_blank\" rel=\"nofollow\">CAHtalyst\u202fAdult\u202fstudy<\/a>\u202fincluded 182 adult patients 18 to 58 years\u202fof age. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an\u202fadditional\u202f20 weeks\u202fof CRENESSITY treatment enabled GC reduction to\u202fphysiologic\u202frange while androstenedione levels were\u202fmaintained\u202for improved.\u202f\u202f\u00a0<\/p>\n<p>Data from the\u202fCAHtalyst\u202fPhase 3 studies supported approval of CRENESSITY by the\u202fU.S.\u202fFood and Drug Administration\u202fin\u202fDecember 2024. The\u202fopen-label extension treatment portions of both studies are ongoing.\u202f\u202f\u00a0<\/p>\n<p>\n        <b>Important Information<\/b>\u202f\u00a0<\/p>\n<p>\n        <b>Approved Uses<\/b>\u202f <br \/>CRENESSITY<b><sup>\u00ae<\/sup><\/b> (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).\u202f\u00a0<\/p>\n<p>\n        <b>IMPORTANT SAFETY INFORMATION<\/b>\u202f\u00a0<\/p>\n<p>\n        <b>Do not take CRENESSITY if you:<\/b>\u202f\u00a0<\/p>\n<p>Are allergic to\u202fcrinecerfont, or any of the ingredients in CRENESSITY.\u202f\u00a0<\/p>\n<p>\n        <b>CRENESSITY may cause serious side effects, including:\u202f<\/b>\u202f\u00a0<\/p>\n<p>\n        <b>Allergic\u202freactions.\u202f<\/b>Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY.\u202f\u00a0<\/p>\n<p>\n        <b>Risk of Sudden Adrenal Insufficiency or Adrenal Crisis\u202fwith\u202fToo Little Glucocorticoid (Steroid) Medicine.\u202f<\/b>Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk\u202ffor\u202fsudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.\u202f\u00a0<\/p>\n<p>\n        <b>Before taking CRENESSITY, tell your healthcare provider about<\/b>\u00a0<b>all of<\/b>\u00a0<b>your medical conditions, including if<\/b>\u00a0<b>you:\u202f<\/b>are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.\u202f\u00a0<\/p>\n<p>\n        <b>Tell your healthcare provider about all the medicines you take,\u202f<\/b>including prescription and over-the-counter medicines,\u00a0vitamins\u00a0and herbal supplements.\u202f\u00a0<\/p>\n<p>\n        <b>The most common side effects of CRENESSITY in adults include\u202f<\/b>tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.\u202f\u00a0<\/p>\n<p>\n        <b>The most common side effects of CRENESSITY in children include<\/b>\u202fheadache, stomach pain, tiredness, nasal congestion, and nosebleeds.\u202f\u00a0<\/p>\n<p>These are not all the possible\u202fside effects of CRENESSITY. Call your healthcare provider for medical advice\u202fabout\u202fside effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch\u202fat\u202f<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=3177297602&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4325283-1%26h%3D2561209654%26u%3Dhttp%253A%252F%252Fwww.fda.gov%252Fmedwatch%26a%3Dwww.fda.gov%252Fmedwatch&amp;a=www.fda.gov%2Fmedwatch\" target=\"_blank\" rel=\"nofollow\">www.fda.gov\/medwatch<\/a>\u202for call 1-800-FDA-1088.\u202f\u00a0<\/p>\n<p>\n        <b>Dosage Forms and Strengths:\u202f<\/b>CRENESSITY is available in 50 mg and\u202f100 mg\u202fcapsules,\u202fand as an oral solution of\u202f50 mg\/mL.\u202f\u00a0<\/p>\n<p>Please see full\u202f<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=1041062155&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4325283-1%26h%3D3091277039%26u%3Dhttp%253A%252F%252Fwww.neurocrine.com%252Fcrenessitypi%26a%3DPrescribing%2BInformation&amp;a=Prescribing+Information\" target=\"_blank\" rel=\"nofollow\"><b>Prescribing Information<\/b><\/a>.\u202f\u00a0<\/p>\n<p>\n        <b>About PWS<\/b><br \/>\n        <br \/>Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in gene expression on chromosome 15.\u00a0The Prader-Willi Syndrome Association USA\u00a0estimates that PWS occurs in one in every 15,000 live births. The defining symptom of PWS is hyperphagia, a chronic and life-threatening condition characterized by an intense persistent sensation of hunger accompanied by food preoccupations, an extreme drive to consume food, food-related behavior problems, and a lack of normal satiety, which can severely diminish the quality of life for individuals with PWS and their families. Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food-seeking behavior) and longer-term comorbidities such as diabetes, obesity, and cardiovascular disease.<\/p>\n<p>\n        <b>About VYKAT\u2122 XR<\/b><br \/>\n        <br \/>VYKAT XR was approved by the\u00a0U.S. Food and Drug Administration\u00a0(FDA) on\u00a0March 26, 2025, and is now commercially available to\u00a0U.S.\u00a0patients.<\/p>\n<p>VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).<\/p>\n<p>\n        <b>INDICATION<\/b><br \/>\n        <br \/>VYKAT XR (diazoxide choline) extended-release tablets is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).<\/p>\n<p>\n        <b>IMPORTANT SAFETY INFORMATION<\/b>\n      <\/p>\n<p>\n        <b>Contraindications<\/b><br \/>\n        <br \/>Use of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.<\/p>\n<p>\n        <b>Warnings and Precautions<\/b>\n      <\/p>\n<p>\n        <b>Hyperglycemia<\/b><br \/>\n        <br \/>Hyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia.<\/p>\n<p>\n        <b>Risk of Fluid Overload<\/b><br \/>\n        <br \/>Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.<\/p>\n<p>\n        <b>Adverse Reactions<\/b><br \/>\n        <br \/>The most common adverse reactions (incidence \u226510% and at least 2% greater than placebo) included hypertrichosis, edema, hyperglycemia, and rash.<\/p>\n<p>Please see the full\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=1350427876&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4690470-1%26h%3D2283527970%26u%3Dhttps%253A%252F%252Fedge.prnewswire.com%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4657525-1%2526h%253D2927326861%2526u%253Dhttps%25253A%25252F%25252Fwww.vykatxr.com%25252Fprescribing-information.pdf%2526a%253DPrescribing%252BInformation%25252C%252Bincluding%252BMedication%252BGuide%26a%3DPrescribing%2BInformation%252C%2Bincluding%2BMedication%2BGuide&amp;a=Prescribing+Information%2C+including+Medication+Guide\" target=\"_blank\" rel=\"nofollow\"><b>Prescribing Information, including Medication Guide<\/b><\/a>.<\/p>\n<p>\n        <b>About Neurocrine<\/b>\u00a0<b>Biosciences, Inc.<\/b>\u00a0\u00a0\u00a0<br \/>Neurocrine Biosciences\u00a0is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders.\u00a0The company&#8217;s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington&#8217;s disease, classic congenital\u00a0adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine\u00a0fibroids*,\u00a0as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=3085014877&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4252873-1%26h%3D4039787179%26u%3Dhttps%253A%252F%252Fwww.neurocrine.com%252F%26a%3Dneurocrine.com&amp;a=neurocrine.com\" target=\"_blank\" rel=\"nofollow\">neurocrine.com<\/a>, and follow the company on <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=3235717981&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fneurocrine&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>, <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=2922839449&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4325283-1%26h%3D3800598244%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4252873-1%2526h%253D3255611529%2526u%253Dhttps%25253A%25252F%25252Ftwitter.com%25252Fneurocrine%2526a%253DX%252B(formerly%252BTwitter)%26a%3DX%2B(formerly%2BTwitter)&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>, <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=1580692651&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4325283-1%26h%3D2508503173%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4252873-1%2526h%253D1536396415%2526u%253Dhttps%25253A%25252F%25252Fwww.facebook.com%25252FNeurocrine%2526a%253DFacebook%26a%3DFacebook&amp;a=Facebook\" target=\"_blank\" rel=\"nofollow\">Facebook<\/a> and\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4701734-1&amp;h=1948809388&amp;u=https%3A%2F%2Fwww.youtube.com%2F%40NeurocrineBiosciencesInc&amp;a=YouTube\" target=\"_blank\" rel=\"nofollow\">YouTube<\/a>.\u00a0<i>(*in collaboration with AbbVie)<\/i>\u00a0\u00a0<\/p>\n<p>The\u00a0NEUROCRINE\u00a0BIOSCIENCES Logo,\u00a0NEUROCRINE, YOU\u00a0DESERVE BRAVE SCIENCE, CRENESSITY and CAHtalyst are\u00a0registered trademarks of Neurocrine Biosciences, Inc. SOLENO is a registered trademark of Soleno Therapeutics, Inc. VYKAT is a trademark of Soleno Therapeutics, Inc.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\u00a0<br \/>In addition to historical facts, this press release\u00a0contains\u00a0forward-looking statements that involve\u00a0a number of\u00a0risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) and VYKAT XR\u00a0for the treatment of Prader-Willi syndrome (PWS); the value and benefits CRENESSITY brings to patients with CAH, including its potential to\u00a0support long-term hormone control and\u00a0glucocorticoid dose reduction;\u00a0the value and benefits VYKAT XR\u00a0brings to patients with PWS, including its potential to support sustained improvements in hyperphagia and behavioral symptoms;\u00a0the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY\u00a0and VYKAT XR; and whether the results from our clinical trials\u00a0and other data\u00a0analyses described in this press release\u00a0are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following:\u00a0risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of CRENESSITY\u00a0or VYKAT XR;\u00a0risks\u00a0and uncertainties associated with Neurocrine Biosciences&#8217; business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY\u00a0and VYKAT XR, including the extent to which patients and physicians accept and adopt CRENESSITY\u00a0and VYKAT XR; whether CRENESSITY\u00a0and VYKAT XR\u00a0receives\u00a0adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY\u00a0or VYKAT XR; risks associated with the Company&#8217;s dependence on third parties for development and manufacturing activities related to CRENESSITY\u00a0and VYKAT XR, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY\u00a0or VYKAT XR\u00a0may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY\u00a0or VYKAT XR; risks that post-approval commitments or requirements\u00a0for CRENESSITY or VYKAT XR\u00a0may be delayed; risks that CRENESSITY\u00a0or VYKAT XR\u00a0may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse;\u00a0and other risks described in the Company&#8217;s periodic reports filed with the Securities and Exchange Commission, including without limitation the Company&#8217;s\u00a0quarterly\u00a0report on Form 10-Q\u00a0for the\u00a0quarter\u00a0ended\u00a0March\u00a031, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.\u00a0\u00a0<\/p>\n<p>\u00a9\u00a02026\u00a0Neurocrine Biosciences, Inc. All Rights Reserved. CAP-CFT-US-0059\u00a0\u00a0\u00a006\/2026<\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA73451&amp;sd=2026-06-03\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-to-present-new-twoyear-crenessity-crinecerfont-data-on-key-clinical-and-patientreported-outcome-measures-at-endo-2026-302789246.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-to-present-new-twoyear-crenessity-crinecerfont-data-on-key-clinical-and-patientreported-outcome-measures-at-endo-2026-302789246.html<\/a><\/p>\n<p>SOURCE Neurocrine Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA73451&amp;Transmission_Id=202606030830PR_NEWS_USPR_____LA73451&amp;DateId=20260603\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuum New data demonstrate the effect of CRENESSITY on long-term androgen control and glucocorticoid dose reduction and associated clinical outcomes Data from cross-sectional surveys highlight patient- and caregiver-reported quality of life improvements Case series highlights use of CRENESSITY in patients with classic CAH due to 11\u03b2\u2011hydroxylase deficiency Additional ENDO 2026 presentations include VYKAT\u2122 XR (diazoxide choline) extended-release tablets data in hyperphagia associated with Prader-Willi syndrome (PWS), including late-breaking long-term extension findings following randomized withdrawal, and data evaluating sustained improvements in hyperphagia and behavioral symptoms through three years SAN DIEGO, June 3, 2026 \/PRNewswire\/ &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-970082","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuum New data demonstrate the effect of CRENESSITY on long-term androgen control and glucocorticoid dose reduction and associated clinical outcomes Data from cross-sectional surveys highlight patient- and caregiver-reported quality of life improvements Case series highlights use of CRENESSITY in patients with classic CAH due to 11\u03b2\u2011hydroxylase deficiency Additional ENDO 2026 presentations include VYKAT\u2122 XR (diazoxide choline) extended-release tablets data in hyperphagia associated with Prader-Willi syndrome (PWS), including late-breaking long-term extension findings following randomized withdrawal, and data evaluating sustained improvements in hyperphagia and behavioral symptoms through three years SAN DIEGO, June 3, 2026 \/PRNewswire\/ &hellip; Continue reading &quot;Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T12:39:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026\",\"datePublished\":\"2026-06-03T12:39:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/\"},\"wordCount\":3063,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/678850\\\/Neurocrine_Biosciences_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/\",\"name\":\"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/678850\\\/Neurocrine_Biosciences_Logo.jpg\",\"datePublished\":\"2026-06-03T12:39:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/678850\\\/Neurocrine_Biosciences_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/678850\\\/Neurocrine_Biosciences_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/","og_locale":"en_US","og_type":"article","og_title":"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026 - Market Newsdesk","og_description":"PR Newswire Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuum New data demonstrate the effect of CRENESSITY on long-term androgen control and glucocorticoid dose reduction and associated clinical outcomes Data from cross-sectional surveys highlight patient- and caregiver-reported quality of life improvements Case series highlights use of CRENESSITY in patients with classic CAH due to 11\u03b2\u2011hydroxylase deficiency Additional ENDO 2026 presentations include VYKAT\u2122 XR (diazoxide choline) extended-release tablets data in hyperphagia associated with Prader-Willi syndrome (PWS), including late-breaking long-term extension findings following randomized withdrawal, and data evaluating sustained improvements in hyperphagia and behavioral symptoms through three years SAN DIEGO, June 3, 2026 \/PRNewswire\/ &hellip; Continue reading \"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-03T12:39:16+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026","datePublished":"2026-06-03T12:39:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/"},"wordCount":3063,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/","name":"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg","datePublished":"2026-06-03T12:39:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neurocrine Biosciences to Present New Two\u2011Year CRENESSITY\u00ae (crinecerfont) Data on Key Clinical and Patient\u2011Reported Outcome Measures at ENDO 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=970082"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970082\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=970082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=970082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=970082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}